黄珺珺，女，1985年11月出生，博士，从事药物化学方向。在药物化学主流期刊European Journal of Medicinal Chemistry，Bioorganic & Medicinal Chemistry, Bioorganic & Medicinal Chemistry Letters, European Journal of Pharmacology, Frontiers in Pharmacology等杂志发表第一及通讯作者SCI论文10余篇，申请专利5项；共主持基金5项，其中国自然1项，省级3项；指导学生获得广州医科大学药学院大学生科技创新项目立项两项。

学习工作经历：

2002/09-2006/06，毕业于暨南大学药学专业，获理学学士学位；2006/07-2009/06，毕业于广州医科大学，师从袁牧教授，获理学硕士学位；2009/07-2012/06，毕业于广州医科大学，师从袁牧教授，获医学博士学位；2012/07-2019/11，广州医科大学药学院药物研发中心，助理研究员，从事教学与科研；

2019/12-至今，广州医科大学药学院药物研发中心，副教授，从事教学与科研；

2020/02-2022/02，赴日本东京大学药学院，访问学者。

【联系邮箱】

huangjunjun1985@gzhmu.edu.cn

【研究方向】

1) 受体药物小分子设计、合成与活性筛选

2) 活性先导物的发现、作用机制与SAR研究

【主要科研项目】

1）广东省自然科学基金面上项目，2021A515010101，从高选择性α_1D/1A亚型阻断剂化合物HJZ-12诱导前列腺细胞凋亡探讨抗前列腺增生症新靶点， 2021/01-2023/12, 10.00万元，在研，主持。

2）国家自然科学基金青年项目，21807017，高选择性α_1D/1A亚型阻断剂AW03类似物的设计、合成及其生物活性研究，2019/01-2021/12，25.00万元，结题，主持。

3）广东省教育厅高校优秀青年创新人才培养项目，2015KQNCX135，芳基哌嗪化合物作为抗前列腺癌药物的设计合成及其作用机制研究，2016/01-2017/12，5.00万元，结题，主持

4）广东省自然科学基金-博士启动纵向协同，2017A030310458，苯基哌嗪类高选择性α_1D/1A亚型阻断剂的设计、合成及其生物活性研究2017/01-2019/12，10.00万元，结题，主持。

5）广州市属高校科研项目青年项目，1201630368，新型苯基哌嗪类α₁亚型受体阻断剂的设计、合成及在良性前列腺增生中的活性评价， 2017/01-2018/12，5.00万元，结题，主持。

6）国家自然科学基金面上项目，21877020，基于结构的新型PPARγ选择性调控剂靶向吲哚衍生物的设计、合成及其抗II型糖尿病作用机制探究，2019/01-2022/12，60.00万元，结题，参加。

7）国家自然科学基金青年项目，81503131，从Naftopidil对映体诱导雄激素代谢探讨抗良性前列腺增生新靶点，2016/01-2018/12，21.48万元，结题，参加。

【主要论文】

1) Junjun Huang, Shihao Song*, Shuo Zhao, Xiuyun Sun, Zijie Wang, Xiaorong Huang, Qing Xiao, Yinyue Deng*, Anti-virulence activity of novel (1-heteroaryloxy-2- hydroxypropyl)- phenylpiperazine derivatives against both wild-type and clinical drug-resistant Candida albicans strains. Microb. Biotechnol., Vol 16, No 1, pp. 116–127, January, 2023

2) QingXiao^#, Qimeng Liu^#, Ruchao Jiang, Kaifeng Chen, Xiang Zhu, Lei Ma, Weixi Li*, Fei He*, Junjun Huang*, Piperazine-derived α_1D/1A antagonist 1- benzyl-N- (3-(4- (2-methoxyphenyl) piperazine-1-yl) propyl) -1H- indole-2- carboxamide induces apoptosis in benign prostatic hyperplasia in dependently of α₁-adrenoceptor blocking. Front. Pharmacol., 11: 594038, January, 2021

3) Qimeng Liu^#, Qing Xiao^#, Xiang Zhu, Kaifeng Chen, Xiawen Liu, Ruchao Jiang, Dan Wu, Junmin Shi, Lijun Dai*, Junjun Huang*, Inhibitory effect of α_1D/1A antagonist 2-(1H-indol-3-yl)-N-[3-(4-(2-methoxyphenyl) piperazinyl) propyl] acetamide on estrogen/androgen induced rat benign prostatic hyperplasia model in vivo, Eur. J. Pharmacol., Vol 870, No 5, pp. 172817–172822, March, 2020

4) Junjun Huang*, Zhihan Zhang, Fei He, Xiawen Liu, Xingjie Xu, Lijun Dai, Qimeng Liu, Mu Yuan*, Novel naftopidil derivatives containing methyl phenylacetate and their blocking effects on α_1D/1A-adrenoreceptor subtypes, Bioorganic Med. Chem. Lett., Vol 28, No 4, pp. 547–551, February, 2018

5) Shuo Zhao^#, Junjun Huang^#, Xiuyun Sun^#, Xiaorong Huang, Shuna Fu, Liang Yang, Xuewei Liu, Fei He*, Yinyue Deng*, (1-aryloxy-2-hydroxypropyl)-phenylpiperazine derivatives suppress Candida albicans virulence by interfering with morphological transition, Microb. Biotechnol., Vol 11, No 6, pp. 1080–1089, September, 2018

6) Wei Xu, Junjun Huang, Renwang Jiang*, Mu Yuan*, Crystal structures, absolute configurations and molecular docking studies of naftopidil enantiomers as α_1D-adrenoceptor antagonists, Acta Pharm. Sin. B, Vol 7, No 4, pp. 496–501, March, 2017

7) Junjun Huang*, Yi Cai, MinYi Huang, Liu Zhu, Fei He, XiaWen Liu, BiYun Huang, YanZhenYi, Mu Yuan*, Pharmaceutical evaluation of naftopidil enantiomers: Rat functional assays in vitro and estrogen/androgen induced rat benign prostatic hyperplasia model in vivo, Eur. J. Pharmacol., Vol 791, No 15, pp. 473–481, September, 2016

8) Wei Xu^#, Junjun Huang^#, Binhao Shao, Xingjie Xu, Renwang Jiang*, Mu Yuan*, Design, synthesis, crystal structure, biological evaluation and molecular docking studies of carbazole-arylpiperazine derivatives, Bioorganic Med. Chem., Vol 24, No 21, pp. 5565–5572, November, 2016

9) Zhihan Zhang^#, Xitian Min^#, Junjun Huang^#, Yue Zhong, Yuehua Wu, Xiaoxia Li, Yinyue Deng, Zide Jiang, Zongze Shao, Lianhui Zhang, Fei He*, Cytoglobosins H and I, New Antiproliferative Cytochalasans from Deep-Sea-Derived Fungus Chaetomium globosum, Marine drugs, Vol 14, No 12, pp. 233–241, December, 2016

10) Junjun Huang^#, Fei He^#, Minyi Huang, Xiawen Liu, Yan Xiong, Yajian Huang, Liu Zhu, Ya Yang, Xingjie Xu, Mu Yuan*, Novel naftopidil-related derivatives and their biological effects as alpha1-adrenoceptors antagonists and antiproliferative agents, Eur. J. Med. Chem., Vol 96, No 26, pp. 83–91, May, 2015

11) Junjun Huang, Yajian Huang, Liu Zhu, Mu Yuan*, Design, synthesis and α₁-adrenoreceptor blocking activity of new arylpiperazine containing acetophenone substituents, Pharmazie, 2014, 69: 578–584.

12) Junjun Huang, Liu Zhu, Yajian Huang, Mu Yuan*, Novel 1-(2- methoxyphenyl)-4-[3-aryloxy-2-hydroxypropyl]-piperazine derivatives and their block effects on α1-Adrenoceptor subtypes, Lat. Am. J. Pharm., 2014, 33 (2): 273–7.

13) Junjun Huang, Mu Yuan*, Separation of substituted phenylpiperazine derivatives with immobilised polysaccharide-based chiral stationary phases by supercritical fluid chromatography, J. Chinese Pharm. Sci., 2013, 22 (3): 244–0.